Upfront Immunotherapy for Metastatic Kidney Cancer
0 Vues
• 06/26/23
0
0
Intégrer
administrator
Les abonnés
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires